Chimeric Antigen Receptor T-Cell Therapy: The Light of Day for Osteosarcoma

SIMPLE SUMMARY: As a novel immunotherapy, chimeric antigen receptor (CAR) T-cell therapy has achieved encouraging results in leukemia and lymphoma. Furthermore, CAR-T cells have been explored in the treatment of osteosarcoma (OS). However, there is no strong comprehensive evidence to support their e...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Zili, Wu, Ziyi, Luo, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431424/
https://www.ncbi.nlm.nih.gov/pubmed/34503279
http://dx.doi.org/10.3390/cancers13174469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431424/
https://www.ncbi.nlm.nih.gov/pubmed/34503279
http://dx.doi.org/10.3390/cancers13174469

Ejemplares similares